Evidence map›Paper›PMID 34377383›Full record

ArticleJournal of oral & maxillofacial research

Therapeutic Approach in the Treatment of Medication-Related Osteonecrosis of the Jaw: Case Series of 3 Patients and State of the Art on Surgical Strategies.

Erica Vettori, Giulia Pipinato, Rossana Bussani, Fulvia Costantinides, Vanessa Nicolin, Lorenzo Bevilacqua, Michele Maglione

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oral & maxillofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Erica VettoriMaxillofacial and Dental Surgical Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, TriesteItaly.
Giulia PipinatoMaxillofacial and Dental Surgical Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, TriesteItaly.
Rossana BussaniPathological Anatomy and Histopathology Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, TriesteItaly.
Fulvia CostantinidesMaxillofacial and Dental Surgical Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, TriesteItaly.
Vanessa NicolinMaxillofacial and Dental Surgical Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, TriesteItaly.
Lorenzo BevilacquaMaxillofacial and Dental Surgical Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, TriesteItaly.
Michele MaglioneMaxillofacial and Dental Surgical Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, TriesteItaly.
University of Trieste · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBisphosphonates and receptor activator of nuclear factor kappa-B ligand inhibitors are currently the most widely used antiresorptive therapies in bone metabolism diseases treatment. Unfortunately they can evoke medication-related osteonecrosis of the jaws. The present case series study proposes to evaluate clinical features, evolution and the surgical therapeutic approaches in three patients affected by medication-related osteonecrosis of the jaw and to review the state of art regarding the management of this complication in light of the most recent literature.

methodsThree cases of medication-related osteonecrosis of the jaws are discussed, two related to bisphosphonates therapy (ibandronic acid) and one due to denosumab.

resultsAll three patients were aged female and had probably a dental trigger agent. The lesions located in posterior mandible were treated in one case with the surgical approach alone and, in the other case, with surgical approach associated with Erb-YAG laser. The lesion related to denosumab was treated with surgical approach and platelet rich fibrin application. A complete healing was always achieved.

conclusionsDentists should be aware of the potential risk of developing medication-related osteonecrosis of the jaws for patients who take or had taken antiresorptive drugs. The side effects of denosumab and bisphosphonates are partly overlapping and currently there is still no consensus about the therapeutic surgical options. Prevention and early detection of the lesions should be the primary strategy.

Indexed as

antiresorptive drugslaser therapyoral surgeryosteonecrosisplatelet-rich fibrin

Identifiers

PMID34377383
PMCPMC8326883
OpenAlexW3191984532

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.